QUALITY IN SPORT
eISSN 2450-3118 · Open Access · Peer-reviewed
apcz.umk.pl/QS Nicolaus Copernicus University in Toruń

Cite as: FERETYCKI, Hubert, KAMINSKAYA, Anhelina, KUREK, Aleksandra, SALAMA, Aladdin, GŁOWACKA, Aleksandra, SAVCHAK, Tetiana, GÓRECKI, Patryk, IVANCHUK, Sofiia, DOMIŃCZAK, Dominika, and ABDULLA, Shafea. Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata. Quality in Sport. 2026;62:73248. https://doi.org/10.12775/QS.2026.62.73248

ARTICLE TIMELINE
Received: 11.06.2026. Revised: 30.06.2026. Accepted: 04.07.2026. Published: 11.07.2026.

The journal has been awarded 20 points in the parametric evaluation by the Polish Ministry of Higher Education and Science (Annex to the announcement of 05.01.2024, No. 32553). Unique Journal Identifier: 201398. Scientific disciplines assigned: Economics and finance (Field of social sciences); Management and Quality Sciences (Field of social sciences).
Punkty Ministerialne z 2019 – aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398. Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych).

Current Trends and Emerging Paradigms in the Treatment of Alopecia Areata

Hubert Feretycki
Cardinal Stefan Wyszynski University in Warsaw, 5 Dewajtis Street, 01-815 Warsaw, Poland
h.feretycki@gmail.com
https://orcid.org/0009-0000-6497-4451

Anhelina Kaminskaya
Medical University of Warsaw (WUM), 61 Żwirki i Wigury Street, 02-091 Warsaw, Poland.
kam.angelina1977@gmail.com
https://orcid.org/0009-0002-1900-1778

Aleksandra Kurek
Medical University of Warsaw (WUM), 61 Żwirki i Wigury Street, 02-091 Warsaw, Poland.
aleksandrakurek01@gmail.com
https://orcid.org/0009-0008-9666-6638

Aladdin Salama
Medical University of Warsaw (WUM)
61 Żwirki i Wigury Street, 02-091 Warsaw, Poland.
aladdin1710@gmail.com
https://orcid.org/0009-0005-2941-1916

Aleksandra Głowacka
Medical University of Warsaw (WUM)
61 Żwirki i Wigury Street, 02-091 Warsaw, Poland
a.glowacka@interia.pl
https://orcid.org/0009-0009-2141-4978

Tetiana Savchak
Medical University of Warsaw (WUM)
61 Żwirki i Wigury Street, 02-091 Warsaw, Poland.
taniasavchak02@gmail.com
https://orcid.org/0009-0002-6829-1281

Patryk Górecki
Medical University of Warsaw (WUM)
61 Żwirki i Wigury Street, 02-091 Warsaw, Poland
gpatryk631@gmail.com
https://orcid.org/0009-0008-0437-6984

Sofiia Ivanchuk
Medical University of Warsaw (WUM)
61 Żwirki i Wigury Street, 02-091 Warsaw, Poland
sonyaivanchuk@gmail.com
https://orcid.org/0009-0007-0008-053X

Dominika Domińczak
Medical University of Lodz
4 Kościuszki Street, 90-419, Lodz, Poland
dominika.dominczak@stud.umed.lodz.pl
https://orcid.org/0009-0008-4911-622X

Shafea Abdulla
Medical University of Warsaw (WUM)
61 Żwirki i Wigury Street, 02-091 Warsaw, Poland
shafea2001@gmail.com
https://orcid.org/0009-0000-1256-8443

Corresponding author:
Hubert Feretycki, h.feretycki@gmail.com

ABSTRACT

Background: Alopecia areata (AA) is an unpredictable, immune-mediated form of non-cicatricial hair loss driven by the collapse of hair follicle immune privilege. Beyond its physical manifestation, the highly visible nature of AA inflicts a profound psychosocial and emotional burden on adult, adolescent, and pediatric populations, severely degrading their quality of life.

Aim: This review evaluates the current trends and major paradigm shifts in the therapeutic landscape of AA, analyzing the transition from traditional, non-specific immunosuppression to targeted molecular and regenerative interventions based on high-level evidence up to 2026.

Materials and methods: A comprehensive synthesis of peer-reviewed literature - including systematic reviews, network meta-analyses, and recent Phase III clinical trial data - was conducted to evaluate the comparative efficacy, safety profiles, and clinical positioning of established and emerging therapies.

Results: Janus kinase inhibitors (baricitinib, ritlecitinib, and deuruxolitinib) demonstrate superior efficacy in moderate-to-severe AA, achieving significant scalp hair regrowth (SALT score of 20 or less). Concurrently, regenerative therapies like exosomes and platelet-rich plasma (PRP) offer effective local alternatives, while structured psychological support significantly reduces patient anxiety and depression.

Conclusion: Targeted and regenerative modalities have fundamentally redefined AA care. However, long-term success is challenged by high relapse rates post-discontinuation and socioeconomic barriers, highlighting the need for personalized maintenance protocols.

Keywords: Alopecia areata; Janus kinase inhibitors; Baricitinib; Ritlecitinib; Deuruxolitinib; JAK/STAT signaling pathway; Regenerative medicine; Exosomes; Platelet-rich plasma (PRP); Trichoscopy

INTRODUCTION

Etiopathogenesis and the Psychosocial Burden of Alopecia Areata

Alopecia areata (AA) is an unpredictable, immune-mediated form of non-cicatricial hair loss characterized by highly variable clinical phenotypes, ranging from circumscribed patches to the total loss of scalp and body hair [24]. Rather than being a merely cosmetic concern, AA is a systemic autoimmune condition with a profound impact on patient well-being. To fully appreciate the therapeutic paradigm shift brought about by modern targeted interventions, it is crucial to understand the cellular mechanisms of the disease in tandem with the substantial psychological toll it inflicts on patients.

The primary pathophysiological driver of alopecia areata is the sudden, localized collapse of the hair follicle's immune privilege. Under normal conditions, anagen-phase hair follicles maintain a strict immune-privileged state by downregulating Major Histocompatibility Complex (MHC) class I and II molecules and producing local immunosuppressive factors. In AA, this protective mechanism fails, leading to an abnormal upregulation of MHC molecules within the follicular epithelium [24].

This aberrant presentation of autoantigens triggers a robust autoimmune response mediated chiefly by autoreactive CD8+ cytotoxic T cells. This inflammatory cascade is orchestrated by an intricate signaling network, where specific chemokines act as critical recruitment signals that actively guide and aggregate immune cells around the hair bulb [29]. The resulting dense, perifollicular lymphocytic infiltration - frequently described as a "swarm of bees" - disrupts

normal hair cycling. It prematurely forces active anagen follicles into the regressive catagen and telogen phases, leading to rapid hair shaft shedding.

The consequences of alopecia areata extend far beyond physical hair loss, imposing a severe psychosocial and emotional burden that profoundly degrades patient-reported quality of life. Because hair is intrinsically linked to body image, self-esteem, and social identity, the highly visible and unpredictable nature of AA often leads to significant psychological distress, including elevated rates of social anxiety, depression, and functional impairment in daily social and professional activities [21].

This burden is uniquely pronounced in pediatric and adolescent populations. Young patients experiencing AA during critical stages of personality development and socialization face intense challenges, including social stigmatization, peer bullying, and profoundly altered self-perception, which can result in long-term emotional distress and social withdrawal [25].

Consequently, addressing the psychological dimensions of AA is increasingly recognized as a vital component of a holistic therapeutic approach. Evidence-based psychological interventions - including mindfulness, stress management, and cognitive behavioral therapy - have demonstrated measurable efficacy in improving mental health outcomes, fostering adaptive coping mechanisms, and potentially supporting overall clinical well-being alongside traditional medical treatments [18].

MATERIALS AND METHODS

2.1. Literature search strategy

To conduct a comprehensive review of current trends in the treatment of alopecia areata (AA), a systematic search of major electronic databases - including PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library - was performed. The search strategy was designed to identify high-quality evidence published between 2016 to 2026, focusing on the evolution of therapeutic modalities. The primary search strings utilized combinations of relevant Medical Subject Headings (MeSH) terms and keywords, including: "alopecia areata", "pathogenesis", "corticosteroids", "Janus kinase inhibitors", "JAK inhibitors", "biologics", "platelet-rich plasma", "exosomes", and "psychosocial impact".

2.2. Inclusion and Exclusion Criteria

Articles were selected based on their relevance to the therapeutic landscape and pathophysiological mechanisms of AA.

- **Inclusion Criteria:** Peer-reviewed systematic reviews, meta-analyses, randomized controlled trials (RCTs), open-label extension studies, and comprehensive narrative reviews. Due to the rapidly evolving nature of targeted therapies, particular emphasis was placed on recent high-level evidence and clinical trials evaluating next-generation compounds.
- **Exclusion Criteria:** Dissertations, case reports with limited sample sizes, non-peer-reviewed preprints, and studies focusing strictly on other forms of non-scarring or scarring alopecias without direct relevance to AA.

2.3. Data Extraction and Synthesis

A total of 32 key bibliographical sources meeting the predefined criteria were selected for rigorous qualitative and quantitative synthesis. Data extraction focused on primary clinical efficacy outcomes - predominantly measured by the Severity of Alopecia Tool (SALT) score - long-term safety profiles, adverse events (AEs), and patient-reported quality of life (QoL) metrics. The gathered literature was categorized into thematic domains: pathophysiology, conventional immunosuppressive therapies, targeted molecular interventions (JAK inhibitors and biologics), regenerative medicine, and psychosocial interventions. This structured approach allowed for a critical comparative analysis of established and emerging therapeutic paradigms.

3. RESULTS

The systematic synthesis of the selected literature revealed distinct outcomes across conventional, targeted, regenerative, and adjuvant therapeutic strategies for alopecia areata (AA). The primary findings are categorized by treatment modality below.

3.1. Conventional Immunosuppressive and Topical Therapies

Conventional treatments continue to serve as the baseline for mild-to-moderate or localized AA, though outcomes vary significantly:

- **Local Corticosteroids:** In a within-patient randomized controlled trial, intralesional betamethasone and triamcinolone acetonide both demonstrated significant efficacy in localized AA, with no statistically significant difference in hair regrowth rates between the two agents [5]. For topical applications, betamethasone valerate combined with minoxidil showed superior efficacy compared to topical latanoprost monotherapy [7].
- **Systemic Immunosuppression:** For severe variants like alopecia totalis (AT) and alopecia universalis (AU), a 2-step double-blind RCT established that combining methotrexate with low-dose prednisone yields significantly higher complete hair regrowth rates than methotrexate monotherapy [10]. Similarly, systematic data confirmed that combining cyclosporine with systemic corticosteroids enhances overall response rates compared to cyclosporine alone, though at the cost of higher transient side effects [22].
- **Minoxidil Monotherapy:** A comprehensive meta-analysis verified that while topical minoxidil improves hair density in mild AA, its efficacy as a systemic or standalone agent in severe cases is limited, frequently requiring combination protocols to achieve satisfactory cosmetic results [17].

3.2. Targeted Molecular Interventions: JAK Inhibitors and Biologics

The largest body of recent high-level evidence focuses on Janus kinase inhibitors (JAKi), which have revolutionized the treatment of moderate-to-severe AA:

- **Baricitinib:** Long-term integrated data from Phase 3 trials spanning up to 4 years demonstrated sustained efficacy, with stable or improving Severity of Alopecia Tool (SALT) scores over time. The safety profile remained consistent with earlier shorter-term trials, showing no new late-onset safety signals [13].
- **Ritlecitinib:** This oral JAK3/TEC family kinase inhibitor demonstrated significant efficacy in both adult and adolescent cohorts. Integrated analyses of the ALLEGRO trials over 24 months showed progressive scalp hair regrowth in patients with severe baseline hair loss, including AT and AU [20, 23]. Open-label long-term data (ALLEGRO-LT) confirmed that ritlecitinib maintains a favorable safety and tolerability profile over extended periods [28].
- **Deuruxolitinib:** The latest Phase 3 randomized, double-blind trial (THRIVE-AA2) evaluating this selective JAK1/2 inhibitor showed that a significantly higher proportion

of adults achieved a SALT score of 20 or less (representing 80% or greater scalp hair coverage) at week 24 compared to the placebo group, presenting rapid onset of action [27].

- **Novel Targets (Etrasimod & Dupilumab):** Beyond JAKi, the Sphingosine-1-phosphate (S1P) receptor modulator etrasimod showed promising Phase 2 efficacy and safety in moderate-to-severe AA [13]. Conversely, targeted biological evaluation of dupilumab (anti-IL-4Rα) in Phase 2a trials demonstrated mixed results, proving highly effective primarily in a subset of AA patients with a concomitant atopic diathesis [8].

The comparative clinical efficacy and safety data extracted from the major network meta-analyses in the literature [15, 30, 31] reveal distinct therapeutic profiles for each class:

- **Oral Baricitinib (4 mg):**
  - *Primary Efficacy:* High clinical response, achieving a SALT score of 20 or less in approximately 35% to 40% of patients at 24 to 36 weeks.
  - *Adverse Events:* Commonly associated with upper respiratory tract infections, acne, headache, and transient lipid elevations.
  - *Evidence Level:* High; supported by systematic reviews and network meta-analyses of randomized controlled trials (RCTs).
- **Oral Ritlecitinib (50 mg):**
  - *Primary Efficacy:* High clinical response, with roughly 30% to 38% of patients reaching the SALT $\leq$ 20 threshold, demonstrating strong efficacy in severe variants like alopecia totalis and universalis.
  - *Adverse Events:* Primarily characterized by headache, nasopharyngitis, mild acne, and transient elevations in creatine kinase.
  - *Evidence Level:* High; verified through integrated Phase III trials and long-term extension data.
- **Oral Deuruxolitinib:**
  - *Primary Efficacy:* Very high clinical response, demonstrating rapid onset of action and a statistically superior proportion of patients reaching a SALT score of 20 or less at week 24 compared to placebo.
  - *Adverse Events:* Frequently presents with acne, headache, nasopharyngitis, and minor variations in laboratory safety monitoring.

    - *Evidence Level:* High; established by recent Phase III randomized, double-blind controlled trial data.
- **Systemic Methotrexate + Prednisone:**
    - *Primary Efficacy:* Moderate-to-high clinical response, highly dependent on the duration of therapy and patient selection.
    - *Adverse Events:* Associated with classic systemic risks including gastrointestinal distress, fatigue, hepatic enzyme elevations, and blood pressure fluctuations.
    - *Evidence Level:* High; demonstrated by rigorous 2-step double-blind RCTs.

3.3. Regenerative Medicine and Procedural Interventions

The literature indicates a growing trend toward using biological and light-based therapies:

- **Platelet-Rich Plasma (PRP):** Systematic reviews confirm that PRP increases hair density and follicle proliferation, serving as a powerful adjuvant therapy when combined with topical treatments like minoxidil [4].
- **Exosome-Based Therapies:** Emerging clinical and experimental evidence highlights exosomes as an effective cell-free regenerative modality that promotes hair follicle regeneration by downregulating local inflammatory signals [3].
- **Phototherapy and Lasers:** Systematic data shows that fractional lasers and phototherapy effectively stimulate hair regrowth in patchy, non-cicatricial alopecia variants, boasting high safety profiles with minimal localized side effects [9].

3.4. Adjuvant and Complementary Approaches

- **Vitamin D Status:** Meta-analyses show a strong clinical correlation between severe AA and deficient serum levels of vitamin D and calcium [15]. Consequently, clinical trials evaluating vitamin D and its topical analogs demonstrated measurable therapeutic benefits in mild-to-moderate AA cases [2].
- **Alternative Medicine:** Systematic evidence supports the efficacy of compound glycyrrhizin as an adjunctive anti-inflammatory agent [14], while clinical data on acupuncture suggests it can offer complementary benefits in managing localized hair loss patches [11].

4. DISCUSSION

The synthesis of recent clinical data outlines a profound paradigm shift in the management of alopecia areata (AA), moving away from broad, non-specific immunosuppression toward highly targeted, molecularly driven interventions. This discussion critically evaluates the therapeutic efficacy, long-term safety trade-offs, and clinical positioning of these emerging modalities within a modern, holistic patient care framework.

4.1. The Targeted Revolution: JAK Inhibitors vs. Conventional Approaches

For decades, the therapeutic baseline for severe AA (including alopecia totalis and alopecia universalis) relied heavily on systemic corticosteroids and broad immunosuppressants like cyclosporine or methotrexate. While regimens such as combining methotrexate with low-dose prednisone can induce remission [10], their clinical utility is severely limited by multi-systemic toxicity, metabolic adverse effects, and a lack of specific molecular targeting.

In contrast, the validation of Janus kinase inhibitors (JAKi) directly addresses the core pathophysiology of AA by disrupting the interferon-gamma-driven JAK/STAT signaling cascade that precipitates immune privilege collapse [24, 29]. Large-scale clinical evidence and network meta-analyses confirm that first-generation and selective next-generation JAKi, such as baricitinib, ritlecitinib, and deuruxolitinib, achieve unprecedented rates of scalp hair regrowth, routinely measured by a SALT score of 20 or less [6, 15, 31]. Deuruxolitinib, a highly selective JAK1/2 inhibitor, has recently demonstrated a particularly rapid onset of action [27], emphasizing the clinical value of selectivity in receptor binding. Furthermore, the efficacy of ritlecitinib in adolescent cohorts [20, 23] fills a historical therapeutic void, providing a high-level evidence option for a population previously limited to less effective topical therapies.

4.2. Long-Term Safety Profiles and the Discontinuation Dilemma

Despite the remarkable efficacy of JAKi, their integration into long-term dermatological practice requires a careful evaluation of safety and maintenance. Integrated data stretching up to 4 years for baricitinib [13] and 24 months for ritlecitinib [28] suggest a stable safety profile, dominated primarily by mild-to-moderate adverse events such as acne, upper respiratory infections, and minor laboratory shifts.

However, a major challenge identified in the literature is the "discontinuation dilemma." Because JAKi act by dynamically suppressing the autoimmune cascade rather than curing the

underlying genetic predisposition, treatment cessation is frequently followed by rapid hair loss relapse [6]. This necessitates indefinite or long-term maintenance protocols, raising significant concerns regarding cumulative financial burden, healthcare accessibility, and the long-term monitoring of rare systemic risks (e.g., thromboembolism or malignancy), which require ongoing real-world evidence (RWE) tracking.

4.3. The Intersect of Regenerative Medicine and Complementary Care

As patients and clinicians seek non-immunosuppressive alternatives or adjunctive therapies, regenerative medicine has emerged as a promising frontier. Platelet-rich plasma (PRP) has well-documented synergistic effects when paired with traditional vasodilators like minoxidil, significantly accelerating localized follicle proliferation [4, 26]. Simultaneously, the clinical synthesis of exosome-based therapies represents a vital evolutionary step [3]. Exosomes offer a cell-free regenerative medium capable of delivering targeted microRNAs and growth factors to the hair bulb, downregulating perifollicular inflammation without the systemic side effects of oral small molecules.

To optimize treatment monitoring across these diverse approaches, the routine clinical adoption of trichoscopy has become indispensable. Systematic reviews show that tracking specific trichoscopic signs (such as exclamation mark hairs, yellow dots, and black dots) allows for the early, non-invasive assessment of disease activity, enabling clinicians to tailor treatment intensities dynamically before macroscopic regrowth or shedding becomes visible [1].

Furthermore, addressing underlying biochemical deficiencies, such as correcting widespread vitamin D and calcium deficiencies [15], serves as a low-risk, evidence-based strategy that enhances follicular receptor responsiveness to primary therapies [2].

4.4. Shifting Toward a Biopsychosocial Model of Care

Perhaps the most crucial insight derived from recent literature is that successful AA management cannot be measured solely by hair follicle density. The profound psychosocial burden of the disease - manifesting as severe anxiety, depression, and social withdrawal across pediatric, adolescent, and adult demographics [21, 25] - demands a transition from a purely biomedical model to a comprehensive biopsychosocial framework.

The integration of formalized psychological interventions (such as mindfulness and cognitive-behavioral stress management) has been shown not only to significantly alleviate mental health distress but also, in some cohorts, to positively influence hair regrowth outcomes [18]. This potential cross-talk underscores the complex neuroendocrine-immune axis governing the hair follicle, where psychological stress can trigger or exacerbate the inflammatory signaling cascades that drive immune privilege collapse.

5. CONCLUSIONS

The therapeutic landscape of alopecia areata (AA) has undergone an unprecedented transformation, evolving from empirical, non-specific immunosuppression to a highly sophisticated era of targeted molecular and regenerative medicine. The evidence synthesized from recent clinical data yields several critical conclusions:

- **The Primacy of Targeted Therapies:** Janus kinase inhibitors (JAKi) - specifically baricitinib, ritlecitinib, and the recently validated deuruxolitinib - represent a revolutionary milestone in dermatological science. By directly targeting the disrupted JAK/STAT pathway, these agents achieve unprecedented rates of scalp hair regrowth in moderate-to-severe AA phenotypes, establishing a new gold standard of care for adults and adolescents alike.
- **The Promise of Regenerative Medicine:** Cell-free and biological therapies, particularly exosome-based interventions and platelet-rich plasma (PRP), offer powerful, non-immunosuppressive alternatives. These modalities stimulate follicle proliferation locally, opening promising avenues for combination protocols or standalone treatments in patients where systemic small molecules are contraindicated.
- **The Biopsychosocial Imperative:** Successful clinical management must extend beyond macroscopic hair density. The severe anxiety, depression, and social stigmatization associated with AA demand the universal adoption of a biopsychosocial care model that integrates formal psychological support and routine quality-of-life monitoring into the primary dermatological framework.

Future Directions

Moving forward, the primary challenge in AA management shifts from proving clinical efficacy to ensuring long-term sustainability and global accessibility. Future clinical research must focus

heavily on resolving the "discontinuation dilemma" through the development of personalized, low-dose maintenance protocols that mitigate the high risk of relapse upon treatment cessation. Furthermore, real-world evidence (RWE) tracking over the next decade will be indispensable in clarifying the lifelong safety profile of cumulative systemic JAK inhibition. Finally, addressing the considerable socioeconomic barriers and high costs associated with these advanced therapies remains a vital priority to ensure that these life-changing molecular innovations are accessible to all affected patient populations globally.

DISCLOSURE

Author's contribution:

- **Conceptualization**: Hubert Feretycki and Patryk Górecki
- **Methodology**: Aleksandra Kurek and Aleksandra Głowacka
- **Investigation**: Tetiana Savchak and Hubert Feretycki and Alladin Salama
- **Data curation**:Shafea Abdulla and Sofiia Ivanchuk
- **Formal analysis**:Maciej Jakub Kozicki and Anhelina Kaminskaya
- **Visualization**:Dominika Domińczak and Aleksandra Kurek
- **Writing - original draft**: Hubert Feretycki and Patryk Górecki
- **Writing - review and editing**: Tetiana Savchak and Sofiia Ivanchuk

Funding Statement The study did not receive special funding.

Institutional Review Board Statement Not applicable (Literature review).

Informed Consent Statement Not applicable.

Data Availability Statement Not applicable.

Conflict of Interest Statement The authors declare no conflicts of interest.

Acknowledgements Not applicable.

Declaration of the use of generative AI In preparing this work, the authors used Gemini (Google) and ChatGPT (OpenAI) for the purpose of assisting with grammar, readability, and structural refinement . All AI tools were used strictly as assistive instruments under human supervision.

REFERENCES

1. Al-Dhubaibi, M. S., Alsenaid, A., Alhetheli, G., & Abd Elneam, A. I. (2023). Trichoscopy pattern in alopecia areata: A systematic review and meta-analysis. *Skin Research and Technology*, *29*, 1–27. https://doi.org/10.1111/srt.13378
2. Alsaati, A. A., Kaliyadan, F., Alsaadoun, D., Alzakry, L. M., Alzabadin, R. A., Hakami, T. H., & Rubaian, N. F. B. (2026). Vitamin D and its analogs in treatment of mild to moderate alopecia areata: Systematic review and meta-analysis. *Indian Dermatology Online Journal*, *17*(1), 10–20. https://doi.org/10.4103/idoj.idoj_958_24
3. Bulgaru-Iliescu, A. I., Moraru, D. C., Amarandei, A.-H., Avadanei-Luca, S., Constantinescu, M.-C., Rusu, A. C., & Pertea, M. (2026). Exosome-based therapies for alopecia areata: A systematic review of clinical and experimental evidence. *International Journal of Molecular Sciences*, *27*(1), Article 21. https://doi.org/10.3390/ijms27010021
4. Cuper, P., Pawłucki, P., Maciak, A., Kozicz, M. A., Jastrzębska, I., Bilecki, K., Gugulski, H., Bado, M., Nowoświat, P., & Sekuła, M. (2024). Complex minoxidil and platelet-rich plasma therapy effectiveness and its impact on physical performance. *Quality in Sport*, *19*, 53183. https://doi.org/10.12775/QS.2024.19.53183
5. De Sousa, V. B., Arcanjo, F. P., Aguiar, F., Vasconcelos, J., Oliveira, A. F., Honório, A., & Pontes, J. (2022). Intralesional betamethasone versus triamcinolone acetonide in the treatment of localized alopecia areata: A within-patient randomized controlled trial. *Journal of Dermatological Treatment*, *33*(2), 875–877. https://doi.org/10.1080/09546634.2020.1788703
6. Egeberg, A., Linsell, L., Johansson, E., et al. (2023). Treatments for moderate-to-severe alopecia areata: A systematic narrative review. *Dermatology and Therapy*, *13*, 2951–2991. https://doi.org/10.1007/s13555-023-01044-5
7. El-Ashmawy, A. A., El-Maadawy, I. H., & El-Maghraby, G. M. (2018). Efficacy of topical latanoprost versus minoxidil and betamethasone valerate on the treatment of alopecia areata. *Journal of Dermatological Treatment*, *29*(1), 55–64. https://doi.org/10.1080/09546634.2017.1330527
8. Guttman-Yassky, E., Renert-Yuval, Y., Bares, J., et al. (2022). Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients. *Allergy*, *77*, 897–906. https://doi.org/10.1111/all.15071

9. Jafari, M. A., Bazgir, G., Hosseini-Baharanchi, F. S., Jafarzadeh, A., & Goodarzi, A. (2024). Efficacy and safety of laser therapy and phototherapy in cicatricial and noncicatricial alopecia: A systematic review study. *Health Science Reports*, *7*, Article e70180. https://doi.org/10.1002/hsr2.70180
10. Joly, P., Lafon, A., Houivet, E., et al. (2023). Efficacy of methotrexate alone vs methotrexate plus low-dose prednisone in patients with alopecia areata totalis or universalis: A 2-step double-blind randomized clinical trial. *JAMA Dermatology*, *159*(4), 403–410. https://doi.org/10.1001/jamadermatol.2022.6687
11. Jun, J. H., Lee, H. W., Choi, T.-Y., & Lee, M. S. (2026). Acupuncture for treating alopecia areata: A systematic review and meta-analysis. *Medicine*, *105*(12), Article e48073. https://doi.org/10.1097/MD.0000000000048073
12. King, B., Mesinkovska, N., Senna, M., Luo, X., Minkiewicz, J., & Selfridge, A. (2025). Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double-blind, placebo-controlled, Phase 2 study. *Journal of the European Academy of Dermatology and Venereology*, *39*, 1174–1184. https://doi.org/10.1111/jdv.20605
13. King, B., Mostaghimi, A., Shimomura, Y., et al. (2025). Safety of baricitinib in adults with severe alopecia areata from two phase III trials over a median of 2.3 years and up to 4 years of treatment. *American Journal of Clinical Dermatology*, *26*, 611–622. https://doi.org/10.1007/s40257-025-00932-0
14. Li, M., Xiang, L., & Li, Y. (2025). Efficacy and safety of compound glycyrrhizin in patients with alopecia areata: A systematic review and meta-analysis. *Annals of Medicine*, *57*(1). https://doi.org/10.1080/07853890.2025.2491659
15. Liu, M., Gao, Y., Yuan, Y., et al. (2023). Janus kinase inhibitors for alopecia areata: A systematic review and meta-analysis. *JAMA Network Open*, *6*(6), Article e2320351. https://doi.org/10.1001/jamanetworkopen.2023.20351
16. Liu, Y., Li, J., Liang, G., et al. (2020). Association of alopecia areata with vitamin D and calcium levels: A systematic review and meta-analysis. *Dermatology and Therapy*, *10*, 967–983. https://doi.org/10.1007/s13555-020-00433-4
17. Majewski, M., Gardaś, K., Waśkiel-Burnat, A., Ordak, M., & Rudnicka, L. (2024). The role of minoxidil in treatment of alopecia areata: A systematic review and meta-analysis. *Journal of Clinical Medicine*, *13*(24), Article 7712. https://doi.org/10.3390/jcm13247712

18. Maloh, J., Engel, T., Natarelli, N., Nong, Y., Zufall, A., & Sivamani, R. K. (2023). Systematic review of psychological interventions for quality of life, mental health, and hair growth in alopecia areata and scarring alopecia. *Journal of Clinical Medicine*, *12*(3), Article 964. https://doi.org/10.3390/jcm12030964
19. Mateos-Haro, M., Novoa-Candia, M., Sánchez Vanegas, G., Correa-Pérez, A., Gaetano Gil, A., Fernández-García, S., Ortega-Quijano, D., Urueña Rodriguez, M. G., Saceda-Corralo, D., Bennouna-Dalero, T., Giraldo, L., Tomlinson, J., Vaño-Galván, S., & Zamora, J. (2023). Treatments for alopecia areata: A network meta-analysis. *Cochrane Database of Systematic Reviews*, (10), Article CD013719. https://doi.org/10.1002/14651858.CD013719.pub2
20. Mesinkovska, N., King, B., Zhang, X., Guttman-Yassky, E., Magnolo, N., Sinclair, R., et al. (2024). Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis. *The Journal of Dermatology*, *51*, 1414–1424. https://doi.org/10.1111/1346-8138.17442
21. Mostaghimi, A., Napatalung, L., Sikirica, V., et al. (2021). Patient perspectives of the social, emotional and functional impact of alopecia areata: A systematic literature review. *Dermatology and Therapy*, *11*, 867–883. https://doi.org/10.1007/s13555-021-00512-0
22. Nowaczyk, J., Makowska, K., Rakowska, A., et al. (2020). Cyclosporine with and without systemic corticosteroids in treatment of alopecia areata: A systematic review. *Dermatology and Therapy*, *10*, 387–399. https://doi.org/10.1007/s13555-020-00370-2
23. Piliang, M., Soung, J., King, B., Shapiro, J., Rudnicka, L., Farrant, P., Magnolo, N., Piraccini, B. M., Luo, X., Wolk, R., Woodworth, D., Schaefer, G., & Lejeune, A. (2025). Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: Integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata. *British Journal of Dermatology*, *192*(2), 215–227. https://doi.org/10.1093/bjd/ljae365
24. Sowińska, T., Łabuda, M., Słojewska, A., Kotkowiak, A., Mentel, O., Bogucka, A., ... Knychalska, K. (2025). Hair loss: Pathogenesis and prevention: A literature review. *Quality in Sport*, *41*, 59999. https://doi.org/10.12775/QS.2025.41.59999

25. Tan, I. J., & Jafferany, M. (2024). Psychosocial impact of alopecia areata in paediatric and adolescent populations: A systematic review. *Journal of Paediatrics and Child Health*, *60*, 778–782. https://doi.org/10.1111/jpc.16678
26. Tejapira, K., Yongpisarn, T., Sakpuwadol, N., & Suchonwanit, P. (2022). Platelet-rich plasma in alopecia areata and primary cicatricial alopecias: A systematic review. *Frontiers in Medicine*, *9*, Article 1058431. https://doi.org/10.3389/fmed.2022.1058431
27. Tsianakas, A., Passeron, T., Magnolo, N., Blume-Peytavi, U., Kelly, V., Day, I., Serrao, R., Guttman-Yassky, E., Sticherling, M., Csernus, A., Moreno-Arrones, O., Hamilton, C., & Cassella, J. (2025). Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial. *Journal of the American Academy of Dermatology*, *94*, 1134–1143. https://doi.org/10.1016/j.jaad.2025.11.070
28. Tziotzios, C., Sinclair, R., Lesiak, A., Mehlis, S., Kinoshita-Ise, M., Tsianakas, A., et al. (2025). Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. *Journal of the European Academy of Dermatology and Venereology*, *39*, 1152–1162. https://doi.org/10.1111/jdv.20526
29. Van Caelenberg, E., Belpaire, A., van Geel, N., & Speeckaert, R. (2025). A meta-analysis of chemokines in alopecia areata: Recruiting immune cells toward the hair follicle. *Frontiers in Immunology*, *16*, Article 1648868. https://doi.org/10.3389/fimmu.2025.1648868
30. Wei, D., Chen, Y., Shen, Y., Xie, B., & Song, X. (2023). Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: A network meta-analysis. *Frontiers in Immunology*, *14*, Article 1152513. https://doi.org/10.3389/fimmu.2023.1152513
31. Yan, T., Wang, T., Tang, M., & Liu, N. (2024). Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: A systematic review and network meta-analysis. *Frontiers in Pharmacology*, *15*, Article 1372810. https://doi.org/10.3389/fphar.2024.1372810
32. Yu, D. A., Kim, Y. E., Kwon, O., & Park, H. (2021). Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis. *Indian Journal of Dermatology, Venereology and Leprology*, *87*, 621–627. https://doi.org/10.25259/ijdvl_975_19